Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

2,000

Employees2,000

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

2,000

Employees2,000

NBIX Key Statistics

Market cap

17.17B

Market cap17.17B

Price-Earnings ratio

26.37

Price-Earnings ratio26.37

Dividend yield

—

Dividend yield—

Average volume

1.07M

Average volume1.07M

High today

$172.57

High today$172.57

Low today

$169.32

Low today$169.32

Open price

$169.77

Open price$169.77

Volume

929.72K

Volume929.72K

52 Week high

$181.18

52 Week high$181.18

52 Week low

$122.14

52 Week low$122.14

Stock Snapshot

With a market cap of 17.17B, Neurocrine(NBIX) trades at $172.00. The stock has a price-to-earnings ratio of 26.37.

On 2026-07-18, Neurocrine(NBIX) stock moved within a range of $169.32 to $172.57. With shares now at $172.00, the stock is trading +1.6% above its intraday low and -0.3% below the session's peak.

Trading volume for Neurocrine(NBIX) stock has reached 929.72K, versus its average volume of 1.07M.

Over the past 52 weeks, Neurocrine(NBIX) stock has traded between a high of $181.18 and a low of $122.14.

NBIX News

Simply Wall St 3h

Is Neurocrine Biosciences Still Undervalued Or Does Its P E Leave Little Upside?

Neurocrine Biosciences (NBIX) stock remains in focus after recent trading saw mixed short term moves, with the share price declining 0.4% over the past day but...

TipRanks 1d

Neurocrine price target raised to $200 from $175 at Wells Fargo

Wells Fargo raised the firm’s price target on Neurocrine (NBIX) to $200 from $175 and keeps an Overweight rating on the shares. Based on robust script trends an...

Simply Wall St 1d

Should Strong Earnings Projections and Zacks Rank #1 Status Require Action From Neurocrine Biosciences Investors? - simplywall.st

...

Analyst ratings

88%

of 32 ratings

Buy

87.5%

Hold

12.5%

Sell

More NBIX News

Nasdaq 4d

Can Neurocrine Run Higher on Rising Earnings Estimates?

Neurocrine Biosciences (NBIX) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong...

Simply Wall St 6d

Krystal Biotech Stock And 2 Biotech Names With Pipeline Catalysts

The latest headlines around AstraZeneca, from its £207b valuation to its multibillion dollar R&D and expansion plans, show how a single company’s choices on inv...

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.